Findings
========

Every year, influenza virus infects 5-20% of the US population with numerous deaths attributed to primary influenza infection or secondary bacterial pneumonia \[[@B1]\]. The rapid evolution of new influenza virus strains and drug resistant variants demands constant development of treatments as well as reliable animal models allowing for testing of these remedies \[[@B2],[@B3]\]. Although a number of animal models are used for influenza research, ferrets are ideal because they can be readily infected with human isolates of influenza virus (in contrast to mice) and exhibit symptoms similar to humans, such as fever, coughing, sneezing, runny nose, lethargy \[[@B4]-[@B10]\], and make a full recovery in 7-10 days \[[@B11],[@B12]\]. Humans and ferrets also share a similar distribution of α-2,6 and α-2,3 linked sialic acid residues, which serve as the receptor for influenza attachment to airway epithelial cells, enabling influenza to use the same cell entry mechanism \[[@B5],[@B13],[@B14]\]. Furthermore, ferrets are large enough to easily monitor aspects of disease progression and yield enough materials for immunological and virological analysis, \[[@B6],[@B15]-[@B17]\]. Prior to clinical trials, safety and efficacy need to be demonstrated in two animal models, one non-rodent, making the ferret ideal.

We examined progression of A/Brisbane/59/2007 in ferrets using a full series of endpoints; clinical symptoms, gross and microscopic pathology, virology, and immunology. A/Brisbane/59/07 was obtained from the Centers for Disease Control and Prevention and propagated for 2 days at 34°C in 10-day embryonated hen\'s eggs \[[@B18]\]. Castrated and de-scented Fitch ferrets (6-8 months of age, 800-1800 grams; Triple F Farms, Sayre, PA) were assigned to one of 6 treatment groups (Table [1](#T1){ref-type="table"}) by a weight-matched computer-generated randomization procedure. Five groups were challenged intranasally with increasing doses of A/Brisbane/59/2007, and controls received PBS. Changes in body temperature, body weight, and onset of clinical symptoms were monitored for 7 days after challenge to measure disease progression and severity. Analyzed specimens included blood sera, and excreta samples from nasal and throat swabs from 1, 3, 5, and 7 DPI and tissues from 3 and 7 DPI. Animal studies were approved by Southern Research Institutional Animal Care and Use Committee and met the recommended animal care guidelines.

###### 

Study design and outline of clinical symptoms

  ---------------------------------------------------------------------------------
  Dose Group   Challenge Material   Infectious dose\*   Symptoms
  ------------ -------------------- ------------------- ---------------------------
  1            PBS                  \--                 None

                                                        

  2            A/Brisbane/59/2007   10^3.8^             Discharge, Nose, Serous\
                                                        Discharge, Nose Purulent\
                                                        Discharge, Eye, Clear

                                                        

  3            A/Brisbane/59/2007   10^4.8^             Discharge, Nose, Serous

                                                        

  4            A/Brisbane/59/2007   10^5.8^             Discharge, Nose, Clear\
                                                        Discharge, Eye, Clear

                                                        

  5            A/Brisbane/59/2007   10^6.8^             Discharge, Nose, Serous\
                                                        Discharge, Eye, Clear\
                                                        Sneezing

                                                        

  6            A/Brisbane/59/2007   10^7.8^             Discharge, Nose, Clear\
                                                        Discharge, Nose, Serous\
                                                        Discharge, Eye, Clear\
                                                        Sneezing
  ---------------------------------------------------------------------------------

\* Infectious dose is measured as 50% egg infectious dose per mL (EID~50~/mL)

Animals in groups infected with higher doses of influenza experienced greater severity in clinical symptoms compared to those in lower dose groups or control animals (Table [1](#T1){ref-type="table"}). Groups infected with influenza demonstrated significant weight loss at 2 through 7 DPI compared to the control group. Animals also exhibited elevated body temperature on 2 DPI. Flu-like symptoms, such as sneezing, and nasal and ocular discharge were seen. Most animals fully recovered by 7 DPI; however, some animals relapsed with a recurrence of clear or serous nasal discharge. Histological analysis of lungs showed a range of pathology, such as bronchiolar epithelial hypertrophy and inflammation. Macroscopic lung lesions consisted of dark/mottled discoloration observed in animals in all dose groups on 3 and 7 DPI. In animals euthanized on 3 and 7 DPI, microscopic lesions consistent with influenza infection were observed in all challenge groups, but not controls. Microscopic lesions in lungs of influenza challenge dose groups consisted of acute inflammation of the alveolus, bronchiole, and bronchiole lumen; chronic inflammation of the alveolus, bronchus, peribronchiolar interstitium and perivascular interstitium; chronic-active inflammation of the alveolus; hemosiderin pigmentation of the perivascular interstitium; type II pneumocyte hyperplasia; bronchiolar hypertrophy; syncytia of the alveolus and bronchiole; and regeneration of the bronchiole. Although the incidence and severity of lesions was variable among dose groups, these parameters tended to be the greatest in animals infected with higher doses of virus. Excluding chronic inflammation of the perivascular interstitium and bronchiolar hypertrophy, which ranged from minimal to mild in severity, lesions noted were minimal in severity (Figure [1](#F1){ref-type="fig"}).

![**Clinical Pathology of A/Brisbane/59/2007 infected ferrets**. (A) Control lung tissue; (B) Lung from ferret challenged with 10^3.8^EID~50~/ml with chronic inflammation in the bronchial glands; (C). Lung from ferret challenged with 10^4.8^EID~50~/ml with bronchiolar epithelial hypertrophy (white arrow) and, neutrophils and macrophages within alveoli and airways (black arrow); (D). Lung of ferret challenged with 10^6.8^EID~50~/ml with a syncytium within an alveolus (see blue arrow). Images were taken at 400x magnification](1743-422X-7-149-1){#F1}

Viral load in swabs and tissues was analyzed by titration to determine the TCID~50~. Briefly, MDCK cells (ATCC, clone CCl-34) were grown in DMEM (4.5 g/L glucose, 10% FBS, 1% penicillin/streptomycin, 2 mM L-glutamine, 0.25 M HEPES (all from Gibco)) and seeded at a density of 30,000 cells per well in 96-well plates then incubated at 37°C overnight. For infection, UltraMDCK media (Lonza) (2 μg/mL Trypsin, 1% penicillin/streptomycin, 1% L-glutamine, and 2.5% HEPES) was used. Cells were inoculated with 10-fold serially diluted samples from swabs or tissue homogenates in quadruplicate format. Plates were incubated 3 days at 37°C, 5% CO~2~and saturated humidity, after which cytopathic effect (CPE) was observed microscopically. The viability was determined using a cell viability assay for the nasal and throat swabs as well as for the nasal turbinates (Cell Titer Aqueous One Reagent, Promega). The lungs were analyzed using A cell based ELISA, since this method proved to be less sensitive to cell toxicity. Briefly, cell plates washed twice with PBS (300 uL/well) and fixed (80% v/v Acetone, 50 μL/well). After three repeats of PBS rinses followed by 10 min RT incubations, mouse-anti-nucleoprotein and mouse anti-matrix protein antibodies (200 ng/mL, 50 μL/well, ATCC) were added. The plates were then incubated for 1 h at RT and washed three times with 300 μL/well of PBS + 0.05% Tween-20 (PBST), after which 200 ng/mL of HRP-conjugated horse anti-mouse IgG (H + L chains) was added to (50 uL per well) and incubated for 1 h at RT. Finally, the plates were developed using TMB 2-component microwell peroxidase substrate kit (KPL). The reaction was stopped using 1 M H~3~PO~4~, and plates were measured at an absorbance of 450 nm. Analysis of nasal turbinates collected on 3 DPI showed similar titers regardless of viral dose administered at challenge. Two animals from group 6 and one animal from group 5 showed presence of virus in the lungs (Figure [2A](#F2){ref-type="fig"}). Results showed dose-dependent infection in throat swabs for 1 and 3 DPI. Dose dependence is also seen for the nasal swabs on 1 DPI (Spearman-Rho non-parametric testing, *r~s~*\> 0.85, Figure [2B](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}). By 7 DPI, all groups returned to baseline levels, indicating that the animals cleared the infection (Figure [2B](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}).

![**TCID~50~Virus Titration Analysis**. Blue dots indicate the titer of individual animals, the red line indicates the average for the animals tested in each group and day. For the caudal lung and nasal turbinates (A), four animals per group were analyzed at 3 DPI. In (B), analysis of throat and nasal swabs isolated at 1, 3, 5, and 7 DPI is shown. Eight samples per group were analyzed on 1 and 3 DPI, and four samples per group were analyzed on days 5 and 7 due to the euthanasia of 50% of the animals on 3 DPI.](1743-422X-7-149-2){#F2}

Immunological parameters were evaluated using virus specific ferret IgG and IgM ELISA on sera collected on 3 and 7 DPI. Briefly, plates were coated with 1:200 dilution of stock virus in PBS overnight at 4°C, blocked with 2% donor goat serum (Sigma Aldrich) in PBS/0.05% v/v Tween-20 for one hour. Ferret serum was then added and 2-fold serially diluted and incubated at 4°C overnight. Anti-ferret IgG or IgM-HRP (1:10,000) (Rockland Immunochemicals) was then added and after a one hour incubation at 37°C, TMB substrate was added, the reaction was stopped using 1 M H~3~PO~4~, and read at absorbance of 450 nm. At 7 DPI, influenza-specific IgM and IgG antibodies increased relative to viral dose administered at challenge (Spearman-Rho non-parametric testing, *r~s~*\> 0.94, Figure [3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}). No change between pre-immune and post-immune sera collected at 3 DPI was detected. Neutralization titer analysis was performed to detect influenza-specific neutralizing antibodies in serum. Only sera collected on 7 DPI was evaluated as ELISA results suggested that no neutralizing antibodies were present on 3 DPI. As expected, no neutralizing antibodies were detected in sera from control animals. Only 2 of 4 animals from group 2 and 1 of 4 animals from group 3 had detectable neutralizing antibodies; however neutralizing antibodies were seen in all animals in groups 4, 5 and 6 which were challenged with higher doses of virus (Figure [3C](#F3){ref-type="fig"}). Hematological analyses were also performed on blood samples collected immediately prior to euthanasia. Results showed an increase in the number of lymphocytes, neutrophils, and the total number of white blood cells in infected groups compared to control (Figure [3D,E,F](#F3){ref-type="fig"}). There was only a slight increase in the number of basophils and eosinophils in groups 4 and 5 compared to controls.

![**Humoral and Cellular Immunity**. (A and B) ELISA data show an increase in influenza specific IgM and IgG at 7 DPI compared to mock-infected control animals. These data show that there is a dose-dependent increase in antibody response. Bars indicate the average difference per group between log~2~-transformed end-point dilutions from pre-infection serum and post-infection serum. (C) Neutralization titer analysis was performed in order to detect the presence of influenza-specific neutralizing antibodies in the serum. The presence of neutralizing antibodies was measured only on 7 DPI. No neutralizing antibodies were detected in the sera from control animals. Only 2 out of 4 animals from group 2 and 1 out of 4 animals from group 3 had detectable neutralizing antibodies, while all animals in groups 4, 5, and 6 had detectable neutralizing antibodies. (D, E, and F) The number of neutrophils and lymphocytes, as well as the total number of white blood cells, increased in animals infected with A/Brisbane/59/07 compared to mock infected control animals. Y axis indicates number of cells as 10^3^cells per mm^3^.](1743-422X-7-149-3){#F3}

To conclude, ferrets infected with A/Brisbane/59/2007 H1N1 displayed mild clinical symptoms, with weight loss, sneezing, nasal and ocular discharge as well as histopathological lesions consistent with influenza infection. Histopathology of the lungs indicated a localized immune response. Virus titers exhibit dose dependence, with higher titers early in the course of infection for the higher doses. Lower doses suggest a delay of virus replication in the samples tested. Homogenized nasal turbinates showed a relatively even distribution over time points. In contrast to a recently published study investigating the pathological effects of a single dose of A/Brisbane/59/2007 \[[@B19]\], we detected replicating virus in the lungs, which indicates that this influenza strain is capable of inducing infection in tissues of the lower respiratory tract. High correlation is seen between viral dose at challenge and the immune response detected by virus specific IgG and IgM ELISA, the neutralization index, and to the viral titers of the throat swabs. To conclude, we describe development of a ferret model for analysis of a seasonal influenza strain. The results provide key endpoints for preclinical testing of the efficacy of new antiviral compounds and experiential vaccines.
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